BCL2 and melanoma: To further validate the effects of increased CD133 expression on trametinib-induced apoptosis, AKT activation, and levels or phosphorylation of pro- and anti-apoptotic BCL-2 family proteins, we compared the consequences of induced CD133 expression in another Dox-inducible melanoma cell line, POT-CD133.